{
  "items": "34",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "HC Wainwright Forecasts enGene's Q1 Earnings (NASDAQ:ENGN)",
      "url": "https://www.marketbeat.com/instant-alerts/hc-wainwright-forecasts-engenes-q1-earnings-nasdaqengn-2025-12-25/",
      "time_published": "20251225T130936",
      "authors": [
        "MarketBeat"
      ],
      "summary": "HC Wainwright has reduced its Q1 2026 EPS estimate for enGene (NASDAQ:ENGN) to ($0.65) but maintained a \"Buy\" rating and a $25 price target, projecting profitability by FY2030. Other firms like Morgan Stanley and Oppenheimer have also recently updated their ratings or price targets, contributing to a \"Moderate Buy\" consensus. Operationally, enGene saw its stock open at $9.45 and reported a Q4 earnings miss.",
      "banner_image": "https://www.marketbeat.com/logos/engene-holdings-inc-logo-1200x675.jpg?v=20231108062701",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.946956"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.801571"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.731980"
        },
        {
          "topic": "finance",
          "relevance_score": "0.640494"
        }
      ],
      "overall_sentiment_score": 0.110385,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.122442",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Engene stock remains a Buy at H.C. Wainwright on NMIBC treatment advantages",
      "url": "https://ng.investing.com/news/analyst-ratings/engene-stock-remains-a-buy-at-hc-wainwright-on-nmibc-treatment-advantages-93CH-2265981",
      "time_published": "20251223T133000",
      "authors": [
        "Investing.com"
      ],
      "summary": "H.C. Wainwright reiterated its Buy rating and a $25.00 price target for Engene Holdings Inc. (NASDAQ:ENGN), citing strong progress with its NMIBC treatment, detalimogene. The company has completed enrollment for its pivotal LEGEND cohort, demonstrating comparable efficacy to other treatments with improved tolerability and administration. Engene's selection for an FDA program and a recent public offering further strengthen its financial position and development timeline.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.847816"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.928415"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.707133"
        }
      ],
      "overall_sentiment_score": 0.45135,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.481859",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Engene stock remains a Buy at H.C. Wainwright on NMIBC treatment advantages",
      "url": "https://m.investing.com/news/analyst-ratings/engene-stock-remains-a-buy-at-hc-wainwright-on-nmibc-treatment-advantages-93CH-4421001?ampMode=1",
      "time_published": "20251223T121007",
      "authors": [
        "Investing.com"
      ],
      "summary": "H.C. Wainwright reiterated its Buy rating and $25.00 price target on Engene Holdings Inc. due to significant progress with its NMIBC treatment, detalimogene. The company has completed enrollment for its pivotal LEGEND cohort, and its treatment offers comparable efficacy with advantages in tolerability and administration. Engene also recently completed a public offering to secure substantial capital and received FDA recognition for its manufacturing development.",
      "banner_image": "https://i-invdn-com.investing.com/msite/img/install_apps/mobile-icon-banner.svg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.923014"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.811064"
        }
      ],
      "overall_sentiment_score": 0.847144,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.802014",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Reports Full Year 2025 Financial Results and Provides Business Update",
      "url": "https://www.biospace.com/press-releases/engene-reports-full-year-2025-financial-results-and-provides-business-update",
      "time_published": "20251223T121007",
      "authors": [
        "NULL"
      ],
      "summary": "enGene Holdings Inc. announced its full-year 2025 financial results, highlighting the completion of enrollment in the LEGEND pivotal cohort and a solid cash position extending its runway into H2 2028. The company reported promising preliminary 6-month complete response rates for its lead therapy, detalimogene, and confirmed its selection for the FDA\u2019s CDRP Program, preparing for a Biologic License Application submission in the second half of 2026. This update positions enGene for continued development of its non-viral genetic medicine for high-risk, BCG-unresponsive non-muscle invasive bladder cancer.",
      "banner_image": "https://mms.businesswire.com/media/20251222676164/en/2159786/22/enGene_Logo.jpg",
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.949290"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.919741"
        }
      ],
      "overall_sentiment_score": 0.672117,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.675035",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Holdings Inc. SEC 10-K Report",
      "url": "https://www.tradingview.com/news/tradingview:c0f8fa3bdb3e3:0-engene-holdings-inc-sec-10-k-report/",
      "time_published": "20251222T210948",
      "authors": [],
      "summary": "enGene Holdings Inc. has released its annual 10-K report, detailing its financial performance, business operations, and future outlook. The clinical-stage biotechnology company, focused on genetic medicine delivery, reported a net loss of $117.3 million and is advancing its lead product candidate, Detalimogene voraplasmid, through clinical trials with a Biologics License Application planned for late 2026. The report also highlights strategic initiatives, capital management, and significant product development, financial, operational, and regulatory risks the company faces.",
      "banner_image": null,
      "source": "TradingView \u2014 Track All Markets",
      "category_within_source": "General",
      "source_domain": "TradingView \u2014 Track All Markets",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.803884"
        }
      ],
      "overall_sentiment_score": -0.016964,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.263689",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MRK",
          "relevance_score": "0.643949",
          "ticker_sentiment_score": "0.145283",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.612007",
          "ticker_sentiment_score": "0.113748",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "enGene Reports Full Year 2025 Financial Results and Provides Business Update",
      "url": "https://www.businesswire.com/news/home/20251222676164/en/enGene-Reports-Full-Year-2025-Financial-Results-and-Provides-Business-Update",
      "time_published": "20251222T210948",
      "authors": [
        "NULL"
      ],
      "summary": "enGene Holdings Inc. announced its full year 2025 financial results, reporting a net loss of $117.3 million. The company completed enrollment in the LEGEND pivotal cohort with 125 patients and reported a preliminary 6-month complete response rate of 62% in post-amendment patients. enGene estimates its cash and marketable securities, bolstered by a recent $140.1 million financing, will provide a cash runway into the second half of 2028, with a Biologic License Application (BLA) submission for detalimogene planned for 2H 2026.",
      "banner_image": "https://mms.businesswire.com/media/20251222676164/en/2159786/4/enGene_Logo.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.925829"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.841780"
        }
      ],
      "overall_sentiment_score": 0.474961,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.463193",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene (NASDAQ:ENGN) Stock Price Up 8.2% - Time to Buy?",
      "url": "https://www.marketbeat.com/instant-alerts/engene-nasdaqengn-stock-price-up-82-time-to-buy-2025-12-11/",
      "time_published": "20251213T060950",
      "authors": [
        "MarketBeat"
      ],
      "summary": "enGene (NASDAQ:ENGN) shares rose 8.2% in mid-day trading with low volume, closing at $8.6660, reflecting a significant price movement despite reduced liquidity. Analyst sentiment is generally positive, resulting in a \"Moderate Buy\" consensus and a target price of $22.38. The clinical-stage biotech company focuses on non-muscle invasive bladder cancer, has a market cap of $576 million, and maintains strong liquidity but reports negative earnings.",
      "banner_image": "https://www.marketbeat.com/logos/engene-holdings-inc-logo-1200x675.jpg?v=20231108062701",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.925680"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.932600"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.800100"
        }
      ],
      "overall_sentiment_score": 0.223951,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.232096",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.637761",
          "ticker_sentiment_score": "0.133776",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ORCL",
          "relevance_score": "0.571180",
          "ticker_sentiment_score": "0.204135",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PLTR",
          "relevance_score": "0.599626",
          "ticker_sentiment_score": "0.341818",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "FDA selects enGene\u2019s bladder cancer therapy for development program",
      "url": "https://www.investing.com/news/company-news/fda-selects-engenes-bladder-cancer-therapy-for-development-program-93CH-4385833",
      "time_published": "20251207T040923",
      "authors": [
        "Investing.com"
      ],
      "summary": "The FDA has chosen enGene Holdings Inc.'s detalimogene voraplasmid, a non-viral gene therapy for bladder cancer, for its Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program. This selection aims to accelerate its manufacturing development and potential for earlier patient access, especially given the company's strong clinical results and analyst optimism. EnGene plans to submit a Biologics License Application in the second half of 2026.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943944"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.733251"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.624933"
        }
      ],
      "overall_sentiment_score": 0.460285,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.499034",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene\u2019s Detalimogene Chosen for FDA Manufacturing Pilot Program",
      "url": "https://www.tipranks.com/news/company-announcements/engenes-detalimogene-chosen-for-fda-manufacturing-pilot-program",
      "time_published": "20251207T040146",
      "authors": [
        "TipsRanks Canadian Auto-Generated Newsdesk"
      ],
      "summary": "enGene Holdings' investigational gene therapy, detalimogene voraplasmid, has been selected for the FDA\u2019s Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program. This inclusion aims to boost the company\u2019s manufacturing readiness and aligns with its clinical development progress for non-muscle invasive bladder cancer (NMIBC). Despite this positive development, TipRanks\u2019 AI Analyst, Spark, rates ENGN as Neutral due to significant financial challenges including no revenue generation and persistent losses.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2068435553-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949581"
        }
      ],
      "overall_sentiment_score": -0.263581,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.267155",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "enGene stock rises after FDA selects bladder cancer therapy for CMC pilot program",
      "url": "https://www.investing.com/news/stock-market-news/engene-stock-rises-after-fda-selects-bladder-cancer-therapy-for-cmc-pilot-program-93CH-4386387",
      "time_published": "20251205T070952",
      "authors": [
        "Investing.com"
      ],
      "summary": "enGene Holdings Inc. (NASDAQ:ENGN) stock increased by 2% after the FDA selected its bladder cancer therapy, detalimogene voraplasmid, for the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. This program facilitates engagement with the FDA on manufacturing strategies for therapies with compressed clinical development timelines. The selection follows positive preliminary results from enGene's LEGEND trial, showing a 62% complete response rate in patients with high-risk, BCG-unresponsive bladder cancer.",
      "banner_image": "https://i-invdn-com.investing.com/news/LYNXNPEB6J0AJ_L.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929030"
        }
      ],
      "overall_sentiment_score": 0.421695,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.431272",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial",
      "url": "https://finviz.com/news/246447/engene-holdings-inc-engn-surging-after-positive-phase-2-legend-trial",
      "time_published": "20251204T220900",
      "authors": [
        "Talha Qureshi"
      ],
      "summary": "enGene Holdings Inc. (NASDAQ: ENGN) has seen its stock surge over 31% after reporting positive results from its Phase 2 LEGEND trial. The company announced an improved complete response rate of 62% at 6 months for Detalimogene voraplasmid in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Analysts maintain a positive outlook with price targets suggesting significant upside, and enGene remains on track for a Biologics License Application submission in the second half of 2026.",
      "banner_image": "NULL",
      "source": "Finviz",
      "category_within_source": "General",
      "source_domain": "Finviz",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.841927"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.722065"
        }
      ],
      "overall_sentiment_score": 0.466084,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.472505",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial",
      "url": "https://www.insidermonkey.com/blog/engene-holdings-inc-engn-surging-after-positive-phase-2-legend-trial-1654696/",
      "time_published": "20251204T220900",
      "authors": [
        "Talha Qureshi"
      ],
      "summary": "enGene Holdings Inc. (NASDAQ:ENGN) has seen its stock surge over 31% following positive results from its Phase 2 LEGEND trial for bladder cancer treatment. Analysts maintain a positive outlook, with price targets suggesting significant upside. The trial data indicates the company is on track for a Biologics License Application submission in late 2026.",
      "banner_image": "https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/12/12130831/JNCE-insidermonkey-1702404509854.jpg?auto=format&fit=clip&expires=1796688000&width=480&height=269",
      "source": "Insider Monkey",
      "category_within_source": "General",
      "source_domain": "Insider Monkey",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934701"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.827922"
        }
      ],
      "overall_sentiment_score": 0.401789,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.401605",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "H.C. Wainwright maintains Buy rating on Engene stock as detalimogene joins FDA pilot program",
      "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-maintains-buy-rating-on-engene-stock-as-detalimogene-joins-fda-pilot-program-93CH-4388299",
      "time_published": "20251204T080958",
      "authors": [
        "Investing.com"
      ],
      "summary": "H.C. Wainwright has reiterated a Buy rating and $25.00 price target for Engene Holdings Inc. (NASDAQ:ENGN) after its detalimogene therapy was selected for the FDA\u2019s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program. This selection, alongside existing FDA designations, is expected to accelerate clinical timelines and support commercial readiness for detalimogene, which is anticipated to file its Biologics License Application (BLA) in the second half of 2026. The firm notes the stock is currently trading at $7.86, with the price target indicating over 200% upside.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.935843"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.735904"
        },
        {
          "topic": "finance",
          "relevance_score": "0.600206"
        }
      ],
      "overall_sentiment_score": 0.46131,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "0.956838",
          "ticker_sentiment_score": "0.450605",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Franklin Resources Inc. Sells 136,866 Shares of enGene Holdings Inc. $ENGN",
      "url": "https://www.marketbeat.com/instant-alerts/filing-franklin-resources-inc-sells-136866-shares-of-engene-holdings-inc-engn-2025-12-03/",
      "time_published": "20251204T040146",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Franklin Resources Inc. has reduced its stake in enGene Holdings Inc. by 11.6%, selling 136,866 shares, but still holds over 1 million shares valued at approximately $3.78 million. Despite this sale, enGene maintains a \"Moderate Buy\" rating from Wall Street analysts with an average price target significantly higher than its current share price. The clinical-stage biotech company is characterized by strong liquidity and low debt, although it has reported negative earnings.",
      "banner_image": "https://www.marketbeat.com/logos/engene-holdings-inc-logo-1200x675.png?v=20231108062701",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.905081"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.829703"
        }
      ],
      "overall_sentiment_score": 0.182425,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.254250",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BEN",
          "relevance_score": "0.715957",
          "ticker_sentiment_score": "0.143036",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RJF",
          "relevance_score": "0.553332",
          "ticker_sentiment_score": "0.219663",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "enGene\u2019s Detalimogene Chosen for FDA Manufacturing Pilot Program",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/ENGN/pressreleases/36430765/engenes-detalimogene-chosen-for-fda-manufacturing-pilot-program/",
      "time_published": "20251203T072800",
      "authors": [
        "NULL"
      ],
      "summary": "enGene Holdings announced that its gene therapy, detalimogene voraplasmid, was selected for the FDA\u2019s Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, aiming to enhance manufacturing readiness and support its clinical development. This selection highlights the therapy's potential for high-risk, non-muscle invasive bladder cancer and enGene's commitment to robust manufacturing, with a Biologics License Application planned by the second half of 2026. Despite a current analyst Buy rating, TipRanks AI Analyst Spark views ENGN as Neutral due to financial challenges and lack of revenue.",
      "banner_image": "NULL",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.921119"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.748894"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.741988"
        },
        {
          "topic": "finance",
          "relevance_score": "0.647590"
        }
      ],
      "overall_sentiment_score": 0.301622,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.327668",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "enGene Holdings Closes $130 Million Public Offering",
      "url": "https://www.tipranks.com/news/company-announcements/engene-holdings-closes-130-million-public-offering",
      "time_published": "20251118T080959",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "enGene Holdings successfully closed a public offering of common shares and pre-funded warrants, raising approximately $130 million. The offering, priced on November 12, 2025, and closed on November 14, 2025, is expected to improve the company's financial standing. Despite a Buy rating from analysts with a $19.00 price target, Spark's AI Analyst rates ENGN as Neutral due to financial challenges like no revenue, persistent losses, and bearish technical indicators.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1423187486-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.904683"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.833789"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.820151"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.737478"
        }
      ],
      "overall_sentiment_score": -0.200508,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.203473",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "enGene Holdings Inc Announces Updates on Phase 2 LEGEND Trial",
      "url": "https://www.tradingview.com/news/tradingview:eda3ca3609d04:0-engene-holdings-inc-announces-updates-on-phase-2-legend-trial/",
      "time_published": "20251117T040146",
      "authors": [
        "NULL"
      ],
      "summary": "enGene Holdings Inc. (ENGN) has announced new preliminary data from its Phase 2 LEGEND trial for detalimogene voraplasmid. The trial completed enrollment with 125 patients, showing a 62% complete response rate at 6 months. The company plans to file a Biologics License Application in the second half of 2026.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928328"
        }
      ],
      "overall_sentiment_score": 0.439497,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.417129",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Holdings (ENGN) Price Target Increased by 10.59% to 24.20",
      "url": "https://www.nasdaq.com/articles/engene-holdings-engn-price-target-increased-1059-2420",
      "time_published": "20251117T012900",
      "authors": [
        "George Maybach"
      ],
      "summary": "Fintel reports that the average one-year price target for enGene Holdings (NasdaqCM:ENGN) has increased by 10.59% to $24.20 per share, up from $21.88. This new target is an average of analyst estimates, with a range from $10.10 to $34.65, representing a 183.73% increase from the last closing price of $8.53. Institutional ownership data shows 46 funds holding positions in ENGN, with a slight decrease in the number of owners but an increase in total shares owned by institutions.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.929835"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.816029"
        },
        {
          "topic": "finance",
          "relevance_score": "0.635327"
        }
      ],
      "overall_sentiment_score": 0.456798,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.463041",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Holdings (ENGN) Is Up 36.9% After Strong Phase 2 Bladder Cancer Gene Therapy Results",
      "url": "https://finance.yahoo.com/news/engene-holdings-engn-36-9-081708363.html",
      "time_published": "20251113T040146",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "enGene Holdings (ENGN) saw its stock rise 36.9% following positive preliminary Phase 2 trial data for its bladder cancer gene therapy, detalimogene voraplasmid, which showed a 62% complete response rate at six months. The company plans to file for regulatory approval in the second half of 2026. While the strong clinical results excite investors and analysts, enGene remains unprofitable and faces future funding and dilution risks common to pre-revenue biotech firms.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905732"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.736731"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.621862"
        },
        {
          "topic": "finance",
          "relevance_score": "0.611212"
        }
      ],
      "overall_sentiment_score": 0.44294,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.444770",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants",
      "url": "https://www.businesswire.com/news/home/20251112537822/en/enGene-Announces-Pricing-of-%24130-Million-Public-Offering-of-Common-Shares-and-Pre-Funded-Warrants",
      "time_published": "20251112T080959",
      "authors": [
        "NULL"
      ],
      "summary": "enGene Holdings Inc. (Nasdaq: ENGN) announced the pricing of a public offering expected to raise approximately $130 million. The offering includes 12,558,823 common shares at $8.50 per share and pre-funded warrants for 2,735,295 shares at $8.4999 per warrant, with an option for underwriters to purchase additional common shares. The offering is anticipated to close around November 14, 2025.",
      "banner_image": "https://mms.businesswire.com/media/20251112537822/en/2159786/4/enGene_Logo.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.934072"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.841813"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.710005"
        }
      ],
      "overall_sentiment_score": 0.43061,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.406035",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Raymond James upgrades enGene stock rating to Strong Buy on positive cancer trial",
      "url": "https://www.investing.com/news/analyst-ratings/raymond-james-upgrades-engene-stock-rating-to-strong-buy-on-positive-cancer-trial-93CH-4349411",
      "time_published": "20251111T071007",
      "authors": [
        "Investing.com"
      ],
      "summary": "Raymond James upgraded enGene Holdings Inc. (NASDAQ:ENGN) to Strong Buy and raised its price target to $27.00 after the biotech company disclosed positive interim results from its Phase 2 LEGEND study for bladder cancer treatment. The stock surged 65% following the announcement, although InvestingPro analysis suggests it may be overvalued. The upgrade is driven by the substantial market opportunity in NMIBC and the promising efficacy of its drug detalimogene.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913254"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.824139"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.707507"
        }
      ],
      "overall_sentiment_score": 0.209885,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.440386",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "RJF",
          "relevance_score": "0.725165",
          "ticker_sentiment_score": "0.300470",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.612688",
          "ticker_sentiment_score": "-0.105824",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "enGene Announces Proposed Public Offering of Common Shares",
      "url": "https://www.businesswire.com/news/home/20251112104478/en/enGene-Announces-Proposed-Public-Offering-of-Common-Shares",
      "time_published": "20251110T080958",
      "authors": [],
      "summary": "enGene Holdings Inc. announced the commencement of an underwritten public offering of its common shares, with an option for underwriters to purchase additional shares. The offering is subject to market conditions, and Jefferies, Leerink Partners, and Wells Fargo Securities are serving as joint book-running managers. The offering is being made pursuant to an effective shelf registration statement filed with the SEC.",
      "banner_image": "https://mms.businesswire.com/media/20251112104478/en/2159786/4/enGene_Logo.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.935608"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.911878"
        }
      ],
      "overall_sentiment_score": -0.103991,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.119550",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial",
      "url": "https://www.businesswire.com/news/home/20251110861491/en/enGene-to-Host-Conference-Call-to-Provide-Update-on-Pivotal-Cohort-of-LEGEND-Trial",
      "time_published": "20251110T040146",
      "authors": [],
      "summary": "enGene Holdings Inc. will host a conference call and webcast on November 11, 2025, to discuss new preliminary data from the pivotal cohort of its LEGEND trial. The trial evaluates their non-viral gene therapy candidate, detalimogene voraplasmid, for high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. A slide deck will accompany the call, and a replay will be available online.",
      "banner_image": "https://mms.businesswire.com/media/20251110861491/en/2159786/4/enGene_Logo.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.847004"
        },
        {
          "topic": "finance",
          "relevance_score": "0.625177"
        }
      ],
      "overall_sentiment_score": 0.305748,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.312171",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "enGene Holdings Inc. (ENGN) Stock forecasts - Yahoo",
      "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_6403f695-ce9c-489c-be9c-c8e1c1841635",
      "time_published": "20251019T034204",
      "authors": [
        "NULL"
      ],
      "summary": "This page is a cookie consent pop-up from Yahoo, stating that it requests user consent to use cookies for various purposes including providing services, authentication, security, and measurement. It also informs users about the use of precise geolocation, personal data for analytics, personalized advertising, and content, giving options to accept all, reject all, or manage privacy settings. The content provided is entirely related to cookie consent and does not contain any information about enGene Holdings Inc. (ENGN) stock forecasts.",
      "banner_image": "NULL",
      "source": "Yahoo",
      "category_within_source": "General",
      "source_domain": "Yahoo",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.503615"
        }
      ],
      "overall_sentiment_score": 0.028604,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "0.333892",
          "ticker_sentiment_score": "0.040004",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "enGene Holdings Inc. (ENGN) reports earnings",
      "url": "https://qz.com/engene-holdings-inc-engn-reports-earnings-1851725808",
      "time_published": "20241219T000000",
      "authors": [
        "Quartz Intelligence Newsroom"
      ],
      "summary": "enGene Holdings Inc. (ENGN) has filed its 10-K report for the fiscal year ended October 31, 2024, detailing a net loss of $55.1 million and an accumulated deficit of $254.7 million. The company, which is focused on developing genetic medicines for bladder cancer, has not yet generated product revenue and faces significant competition and regulatory risks. enGene Holdings also reported material weaknesses in its internal financial controls and is planning to commercialize its product candidates in the U.S. and selected international markets.",
      "banner_image": null,
      "source": "qz.com",
      "category_within_source": "General",
      "source_domain": "qz.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.947272"
        },
        {
          "topic": "finance",
          "relevance_score": "0.646449"
        }
      ],
      "overall_sentiment_score": 0.013638,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "0.317111",
          "ticker_sentiment_score": "0.028911",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "enGene Reports Full Year 2024 Financial Results and Provides a Business Update",
      "url": "https://www.businesswire.com/news/home/20241219627723/en/enGene-Reports-Full-Year-2024-Financial-Results-and-Provides-a-Business-Update",
      "time_published": "20241219T000000",
      "authors": [],
      "summary": "enGene Holdings Inc. reported its full-year 2024 financial results, highlighted by $297.9 million in cash, cash equivalents, and marketable securities, providing a runway into 2027. The company provided updates on its LEGEND Phase 2 study for detalimogene voraplasmid in NMIBC patients, including a 71% anytime complete response rate in preliminary pivotal cohort data and the expansion of the study across all four cohorts with maintenance dosing. enGene also announced key executive appointments, strengthening its leadership team.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.930986"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.826622"
        }
      ],
      "overall_sentiment_score": 0.425075,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.417329",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - October 22, 2024",
      "url": "https://www.biospace.com/press-releases/engene-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-october-22-2024",
      "time_published": "20241023T000000",
      "authors": [],
      "summary": "enGene Holdings Inc. reported the grant of an inducement equity award to its newly-appointed Chief Technology Officer, Joan Connolly. The award consists of a non-qualified stock option to purchase 210,000 common shares at an exercise price of $9.83 per share. This grant was made as a material inducement for Ms. Connolly to join the Company, in accordance with NASDAQ Listing Rule 5635(c)(4).",
      "banner_image": null,
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928116"
        },
        {
          "topic": "finance",
          "relevance_score": "0.701765"
        }
      ],
      "overall_sentiment_score": 0.275429,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.286858",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update",
      "url": "https://www.stocktitan.net/news/ENGN/en-gene-reports-third-quarter-2024-financial-results-and-provides-a-57u5vffibvbv.html",
      "time_published": "20240910T163300",
      "authors": [],
      "summary": "enGene Holdings Inc. reported its financial results for the third quarter ended July 31, 2024, highlighting cash and cash equivalents of $257.7 million, providing a runway into 2027. The company announced it remains on track to release preliminary data from its pivotal LEGEND study in September 2024 for its lead investigational product, detalimogene voraplasmid, for non-muscle invasive bladder cancer. Net loss attributable to common shareholders for the quarter was $14.1 million, or $0.32 per share, primarily due to increased operating expenses related to manufacturing and clinical costs for the LEGEND study.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.931586"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.807129"
        }
      ],
      "overall_sentiment_score": 0.345255,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.310315",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Trimarchi becomes president, COO of BridgeBio",
      "url": "https://www.biocentury.com/article/653058/trimarchi-becomes-president-coo-of-bridgebio",
      "time_published": "20240724T225800",
      "authors": [
        "Richard Guy",
        "Gunjan Ohri"
      ],
      "summary": "BridgeBio Pharma Inc. has appointed Thomas Trimarchi as its new president and COO, a newly created position. Trimarchi previously served as chief product officer for the gene therapy company. Additionally, the article notes leadership changes at Beacon Therapeutics Holdings Ltd., with Lance Baldo becoming CEO and Thomas Biancardi becoming CFO in August.",
      "banner_image": null,
      "source": "BioCentury",
      "category_within_source": "General",
      "source_domain": "BioCentury",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.938689"
        }
      ],
      "overall_sentiment_score": 0.120885,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "0.749643",
          "ticker_sentiment_score": "0.123038",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "enGene Tackles Nonmuscle-Invasive Bladder Cancer With Expansive Phase 1/2 LEGEND Trial for Gene Therapy EG-70",
      "url": "https://www.cgtlive.com/view/engene-tackles-nonmuscle-invasive-bladder-cancer-expansive-phase-1-2-legend-trial-gene-therapy-eg-70",
      "time_published": "20240624T000000",
      "authors": [
        "Noah Stansfield"
      ],
      "summary": "enGene is expanding its Phase 1/2 LEGEND clinical trial for EG-70, a gene therapy for nonmuscle-invasive bladder cancer (NMIBC). The trial will include new cohorts, such as patients with high-risk BCG-unresponsive papillary-only NMIBC and separate cohorts for BCG-naive and BCG-exposed NMIBC with CIS. The company plans to release interim data for the BCG-unresponsive cohort by the end of September 2024 and aims for EG-70 to be a practice-friendly option for various bladder cancer indications.",
      "banner_image": null,
      "source": "CGTLive\u00ae",
      "category_within_source": "General",
      "source_domain": "CGTLive\u00ae",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.030558,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "0.340766",
          "ticker_sentiment_score": "0.026253",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development",
      "url": "https://www.prnewswire.com/news-releases/engene-announces-hiring-of-dr-raj-pruthi-as-senior-vice-president-urologic-oncology-and-clinical-development-302111799.html",
      "time_published": "20240409T085600",
      "authors": [],
      "summary": "enGene Holdings Inc. has announced the hiring of Dr. Raj Pruthi as its Senior Vice President, Urologic Oncology and Clinical Development. Dr. Pruthi brings over 25 years of experience in urology and will be responsible for supporting the clinical development of EG-70, a lead product candidate for non-muscle invasive bladder cancer. His appointment is expected to strengthen enGene's team as they advance their pivotal LEGEND study and explore new urologic indications.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.462142,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.489617",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Reports Full Year 2023 Financial Results and Recent Operational Progress",
      "url": "https://www.stocktitan.net/news/ENGN/en-gene-reports-full-year-2023-financial-results-and-recent-8vdtr2xouy71.html",
      "time_published": "20240129T070000",
      "authors": [],
      "summary": "enGene Holdings Inc. reported its full-year 2023 financial results and provided a corporate update, highlighting significant progress in its lead program, EG-70, for non-muscle invasive bladder cancer. The company achieved primary and secondary endpoints in the Phase 1 portion of the LEGEND study, completed a reverse merger, and secured an expanded $50 million debt facility, extending its cash runway into Q2 2025. Interim clinical data for the pivotal LEGEND study is expected in mid-2024.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.922169"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.817967"
        },
        {
          "topic": "finance",
          "relevance_score": "0.615157"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.641954"
        }
      ],
      "overall_sentiment_score": 0.322357,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.305797",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors",
      "url": "https://www.citybiz.co/article/501300/engene-appoints-lota-s-zoth-cpa-as-member-of-the-board-of-directors/",
      "time_published": "20231219T143131",
      "authors": [],
      "summary": "enGene Holdings Inc. (Nasdaq: ENGN) has appointed Lota S. Zoth, CPA, to its Board of Directors and as Audit Committee Chair. Ms. Zoth brings over two decades of financial and accounting leadership experience, having served as CFO of MedImmune, Inc. and in board roles for several publicly traded companies. This appointment strengthens enGene's financial leadership as it advances its pivotal trial for EG-70 in bladder cancer.",
      "banner_image": null,
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904983"
        },
        {
          "topic": "finance",
          "relevance_score": "0.707850"
        }
      ],
      "overall_sentiment_score": 0.48644,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.486851",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "enGene Appoints Ryan Daws as Chief Financial Officer",
      "url": "https://www.citybiz.co/article/494115/engene-appoints-ryan-daws-as-chief-financial-officer/",
      "time_published": "20231129T143131",
      "authors": [],
      "summary": "enGene Holdings Inc. (NASDAQ: ENGN) (NASDAQ: ENGNW) has appointed Ryan Daws as its Chief Financial Officer and Head of Business Development. Daws brings nearly 25 years of life sciences-focused operational and deal-making experience, including previous CFO roles at Obsidian Therapeutics and Concert Pharmaceuticals. His appointment comes at a critical time as enGene progresses its pivotal EG-70 clinical study for BCG-unresponsive non-muscle invasive bladder cancer and looks forward to interim data in mid-2024.",
      "banner_image": null,
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.939655"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.714266"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.618945"
        }
      ],
      "overall_sentiment_score": 0.516269,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENGN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.549252",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}